Literature DB >> 18391113

Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells.

Laura E Fredenburgh1, Olin D Liang, Alvaro A Macias, Thomas R Polte, Xiaoli Liu, Dario F Riascos, Su Wol Chung, Scott L Schissel, Donald E Ingber, S Alex Mitsialis, Stella Kourembanas, Mark A Perrella.   

Abstract

BACKGROUND: Cyclooxygenase-2 (COX-2) is upregulated in pulmonary artery smooth muscle cells (PASMCs) during hypoxia and may play a protective role in the response of the lung to hypoxia. Selective COX-2 inhibition may have detrimental pulmonary vascular consequences during hypoxia. METHODS AND
RESULTS: To investigate the role of COX-2 in the pulmonary vascular response to hypoxia, we subjected wild-type and COX-2-deficient mice to a model of chronic normobaric hypoxia. COX-2-null mice developed severe pulmonary hypertension with exaggerated elevation of right ventricular systolic pressure, significant right ventricular hypertrophy, and striking vascular remodeling after hypoxia. Pulmonary vascular remodeling in COX-2-deficient mice was characterized by PASMC hypertrophy but not increased proliferation. Furthermore, COX-2-deficient mice had significant upregulation of the endothelin-1 receptor (ET(A)) in the lung after hypoxia. Similarly, selective pharmacological inhibition of COX-2 in wild-type mice exacerbated hypoxia-induced pulmonary hypertension and resulted in PASMC hypertrophy and increased ET(A) receptor expression in pulmonary arterioles. The absence of COX-2 in vascular smooth muscle cells during hypoxia in vitro augmented traction forces and enhanced contractility of an extracellular matrix. Treatment of COX-2-deficient PASMCs with iloprost, a prostaglandin I(2) analog, and prostaglandin E(2) abrogated the potent contractile response to hypoxia and restored the wild-type phenotype.
CONCLUSIONS: Our findings reveal that hypoxia-induced pulmonary hypertension and vascular remodeling are exacerbated in the absence of COX-2 with enhanced ET(A) receptor expression and increased PASMC hypertrophy. COX-2-deficient PASMCs have a maladaptive response to hypoxia manifested by exaggerated contractility, which may be rescued by either COX-2-derived prostaglandin I(2) or prostaglandin E(2).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391113      PMCID: PMC2586933          DOI: 10.1161/CIRCULATIONAHA.107.716241

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

1.  Traction fields, moments, and strain energy that cells exert on their surroundings.

Authors:  James P Butler; Iva Marija Tolić-Nørrelykke; Ben Fabry; Jeffrey J Fredberg
Journal:  Am J Physiol Cell Physiol       Date:  2002-03       Impact factor: 4.249

2.  Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia.

Authors:  T Minamino; H Christou; C M Hsieh; Y Liu; V Dhawan; N G Abraham; M A Perrella; S A Mitsialis; S Kourembanas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  p27(Kip1) is important in modulating pulmonary artery smooth muscle cell proliferation.

Authors:  B W Fouty; B Grimison; K A Fagan; T D Le Cras; J W Harral; M Hoedt-Miller; R A Sclafani; D M Rodman
Journal:  Am J Respir Cell Mol Biol       Date:  2001-11       Impact factor: 6.914

4.  Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.

Authors:  D Praticò; C Tillmann; Z B Zhang; H Li; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

5.  Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling.

Authors:  Y Hoshikawa; N F Voelkel; T L Gesell; M D Moore; K G Morris; L A Alger; S Narumiya; M W Geraci
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

6.  Role of prostacyclin in the cardiovascular response to thromboxane A2.

Authors:  Yan Cheng; Sandra C Austin; Bianca Rocca; Beverly H Koller; Thomas M Coffman; Tilo Grosser; John A Lawson; Garret A FitzGerald
Journal:  Science       Date:  2002-04-19       Impact factor: 47.728

7.  Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat.

Authors:  H Christou; T Morita; C M Hsieh; H Koike; B Arkonac; M A Perrella; S Kourembanas
Journal:  Circ Res       Date:  2000-06-23       Impact factor: 17.367

8.  Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells.

Authors:  Xudong Yang; Karen K K Sheares; N Davie; Paul D Upton; Graham W Taylor; Jo Horsley; John Wharton; Nicholas W Morrell
Journal:  Am J Respir Cell Mol Biol       Date:  2002-12       Impact factor: 6.914

9.  Gbetagamma-mediated prostacyclin production and cAMP-dependent protein kinase activation by endothelin-1 promotes vascular smooth muscle cell hypertrophy through inhibition of glycogen synthase kinase-3.

Authors:  Sebastien Taurin; Kyle Hogarth; Nathan Sandbo; Douglas M Yau; Nickolai O Dulin
Journal:  J Biol Chem       Date:  2007-05-19       Impact factor: 5.157

10.  Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension.

Authors:  Stephen J Wort; Mandy Woods; Timothy D Warner; Timothy W Evans; Jane A Mitchell
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

View more
  37 in total

1.  Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis.

Authors:  Laura E Fredenburgh; Margarita M Suárez Velandia; Jun Ma; Torsten Olszak; Manuela Cernadas; Joshua A Englert; Su Wol Chung; Xiaoli Liu; Cynthia Begay; Robert F Padera; Richard S Blumberg; Stephen R Walsh; Rebecca M Baron; Mark A Perrella
Journal:  J Immunol       Date:  2011-10-03       Impact factor: 5.422

2.  Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.

Authors:  Yi Jin; Thomas J Calvert; Bernadette Chen; Louis G Chicoine; Mandar Joshi; John Anthony Bauer; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

3.  EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling.

Authors:  Ankang Lu; Caojian Zuo; Yuhu He; Guilin Chen; Lingjuan Piao; Jian Zhang; Bing Xiao; Yujun Shen; Juan Tang; Deping Kong; Sara Alberti; Di Chen; Shenkai Zuo; Qianqian Zhang; Shuai Yan; Xiaochun Fei; Fei Yuan; Bin Zhou; Shengzhong Duan; Yu Yu; Michael Lazarus; Yunchao Su; Richard M Breyer; Colin D Funk; Ying Yu
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

4.  Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling.

Authors:  Hsin-Yuan Cheng; Anping Dong; Manikandan Panchatcharam; Paul Mueller; Fanmuyi Yang; Zhenyu Li; Gordon Mills; Jerold Chun; Andrew J Morris; Susan S Smyth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-20       Impact factor: 8.311

Review 5.  Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation.

Authors:  Eric J Belin de Chantemele; David W Stepp
Journal:  J Mol Cell Cardiol       Date:  2011-08-26       Impact factor: 5.000

6.  Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.

Authors:  Paul B Dieffenbach; Christina Mallarino Haeger; Anna Maria F Coronata; Kyoung Moo Choi; Xaralabos Varelas; Daniel J Tschumperlin; Laura E Fredenburgh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-06-22       Impact factor: 5.464

7.  MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach.

Authors:  Victoria N Parikh; Richard C Jin; Sabrina Rabello; Natali Gulbahce; Kevin White; Andrew Hale; Katherine A Cottrill; Rahamthulla S Shaik; Aaron B Waxman; Ying-Yi Zhang; Bradley A Maron; Jochen C Hartner; Yuko Fujiwara; Stuart H Orkin; Kathleen J Haley; Albert-László Barabási; Joseph Loscalzo; Stephen Y Chan
Journal:  Circulation       Date:  2012-02-27       Impact factor: 29.690

8.  Targeted deletions of cyclooxygenase-2 and atherogenesis in mice.

Authors:  Yiqun Hui; Emanuela Ricciotti; Irene Crichton; Zhou Yu; Dairong Wang; Jane Stubbe; Miao Wang; Ellen Puré; Garret A FitzGerald
Journal:  Circulation       Date:  2010-06-07       Impact factor: 29.690

Review 9.  Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Stephen Y Chan; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-24       Impact factor: 4.733

10.  Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension.

Authors:  Fei Liu; Christina Mallarino Haeger; Paul B Dieffenbach; Delphine Sicard; Izabela Chrobak; Anna Maria F Coronata; Margarita M Suárez Velandia; Sally Vitali; Romain A Colas; Paul C Norris; Aleksandar Marinković; Xiaoli Liu; Jun Ma; Chase D Rose; Seon-Jin Lee; Suzy A A Comhair; Serpil C Erzurum; Jacob D McDonald; Charles N Serhan; Stephen R Walsh; Daniel J Tschumperlin; Laura E Fredenburgh
Journal:  JCI Insight       Date:  2016-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.